{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:53:01Z","timestamp":1792979581351,"version":"4.5.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a low-grade B-cell lymphoproliferative disorder. It is the most prevalent type of leukemia in the western countries, with a median age at diagnosis of 70 years. In 2023, it is estimated that there will be 18,740 new cases of CLL, and an estimated 4,490 people will die of this disease. It represents 1.0% of all new cancer cases in the U.S. The rate of new cases was 4.6 per 100,000 men and women per year based on 2016\u20132020 cases, age-adjusted. Death rates from CLL are higher among older adults, or those 75 and older. The death rate was 1.1 per 100,000 men and women per year based on 2016\u20132020 deaths, age-adjusted. A common question that patients with CLL ask during their first clinic visit is: \u201cHow long will it be before I would need treatment?\u201d Although this might seem like a simple question, the answer is not straight forward. CLL is a heterogenous disease, with a variable clinical course. Some patients may present with an aggressive disease requiring early initiation of treatment, while others have an indolent course and some, having so called smoldering CLL, may never need treatment. The variability in disease course can make predicting disease prognosis a complicated process. This brings forth the importance of establishing prognostic models that can predict disease course, time to treatment, and survival outcomes in such a heterogenous disease. The Rai and Binet staging systems were developed in the late 1970s to early 1980s. They separated patients into different stages based on clinical characteristics and laboratory findings. These simple staging systems are still in use; however, several prognostic markers need to be added for an individualized assessment and, with the recent development of genomic techniques leading to better understanding of CLL at the molecular level, newer prognostic markers have emerged.<\/jats:p>","DOI":"10.3389\/fonc.2024.1371057","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:35:50Z","timestamp":1715819750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["An overview of prognostic markers in patients with CLL"],"prefix":"10.3389","volume":"14","author":[{"given":"Julie","family":"Braish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"B1","unstructured":"Surveillance Epidemiology and End Results Cancer Statistics review2009"},{"key":"B2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet JL","year":"1981","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.631638","article-title":"Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia","volume":"53","author":"Seiffert M","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v46.2.219.bloodjournal462219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai KR","year":"1975","journal-title":"Blood"},{"key":"B6","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2017","journal-title":"The Lancet Oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02969.x","article-title":"Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance","volume":"62","author":"Montserrat","year":"1986","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871201)60:11<2712::aid-cncr2820601122>3.0.co;2-","article-title":"Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia","volume":"60","author":"Molica S","year":"1987","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.009","article-title":"Prognostic factors and risk stratification in chronic lymphocytic leukemia","volume":"43","author":"Parikh","year":"2016","journal-title":"Semin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29794","article-title":"B2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"key":"B12","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"key":"B13","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.6.1840.418k06_1840_1847","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais F","year":"1998","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90009-4","article-title":"The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire","volume":"15","author":"Schroeder","year":"1994","journal-title":"Immunol Today"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01280-8","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations","volume":"35","author":"Jain","year":"2021","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0727-y","article-title":"Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group","volume":"34","author":"Hoechstetter","year":"2020","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13743","article-title":"Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait","volume":"108","author":"Brieghel","year":"2022","journal-title":"Eur J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-136109","article-title":"Five-year analysis of murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx)","volume":"136","author":"Kater","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia","volume":"200","author":"Messmer BT","year":"2004","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00005-2","article-title":"Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study","volume":"1","author":"Baliakas","year":"2014","journal-title":"Lancet Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099564","article-title":"Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis","volume":"111","author":"Murray","year":"2008","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0303-x","article-title":"The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia","volume":"33","author":"ten Hacken E","year":"2019","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e52-3","DOI":"10.1016\/S2352-3026(14)00002-7","article-title":"B-cell receptor stereotypy and chronic lymphocytic leukaemia author links open overlay panel","volume":"1","author":"Michallet","year":"2014","journal-title":"Lancet Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell Malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00222-3","article-title":"Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia","volume":"8","author":"Yun X","year":"2020","journal-title":"biomark Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.879715","article-title":"Stereotyped B-cell receptors in chronic lymphocytic leukemia","volume":"55","author":"Agathangelidis A","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184853","article-title":"Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens","volume":"113","author":"Lin","year":"2009","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic Lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a \u201cCLL prognostic index\u201d: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205622","article-title":"Relevance of TP53 for CLL diagnostics","volume":"72","author":"Catherwood MA","year":"2019","journal-title":"J Clin Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u2014update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2174\/1568009616666160809102219","article-title":"Functional and clinical significance of the integrin alpha chain CD49d expression in chronic Lymphocytic leukemia","volume":"16","author":"Dal Bo","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"key":"B48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Kr\u00f6ber","year":"2006","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/cyto.b.20137","article-title":"ZAP-70 in CLL: Towards standardization of a biomarker for patient management: History of clinical cytometry special issue","author":"Marti G","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4065\/79.3.388","article-title":"Current approach to diagnosis and management of chronic Lymphocytic leukemia","volume":"79","author":"Shanafelt","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi806","article-title":"ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia","volume":"16","author":"Hallek M","year":"2005","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186684","article-title":"Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review","volume":"103","author":"Autore F","year":"2018","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150722","article-title":"Normal FISH CLL represents a heterogeneous subgroup where prognosis can be refined with IGHV mutational status","volume":"138","author":"Miller","year":"2021","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb06","article-title":"Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia","volume":"58","author":"Pittman","year":"1984","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23618","article-title":"Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data: Translocations and karyotype complexity in CLL","volume":"89","author":"Baliakas","year":"2014","journal-title":"Am J Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-772285","article-title":"comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"Rigolin GM","year":"2017","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinibbased regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3324\/haematol.2011.057109","article-title":"ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter","volume":"97","author":"Rossi","year":"2012","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26140","article-title":"Outcomes in CLL patients with NOTCH1 regulatory pathway mutations","volume":"96","author":"Helbig","year":"2021","journal-title":"Am J Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.098574","article-title":"ATM mutation rather than BIRC3 deletion and\/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial","volume":"99","author":"Rose-Zerilli","year":"2014","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1548","article-title":"BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-\u03baB nuclear translocation","volume":"25","author":"Daniela Asslaber","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Mart\u00ednez-Trillos","year":"2014","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/jcm9020593","article-title":"Role of non-coding RNAs in the development of targeted therapy and immunotherapy approaches for chronic Lymphocytic leukemia","volume":"9","author":"Pepe","year":"2020","journal-title":"J Clin Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncrna.2020.02.001","article-title":"Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions","volume":"5","author":"Buhagiar A","year":"2020","journal-title":"Noncoding RNA Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32894","article-title":"Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study: Serum miRNA levels before CLL diagnosis","volume":"147","author":"Casabonne","year":"2020","journal-title":"Int J Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-16","article-title":"Epigenetic inactivation of the MIR129-2 in hematological Malignancies","volume":"6","author":"Wong","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12581","article-title":"Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations","volume":"25","author":"Grenda","year":"2022","journal-title":"Mol Med Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478222","article-title":"Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia","volume":"122","author":"Ferrajoli","year":"2013","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian S","year":"2022","journal-title":"Front Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340364","article-title":"An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737","volume":"118","author":"Al-Harbi","year":"2011","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3344","article-title":"The LPL\/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia","volume":"106","author":"Oppezzo","year":"2005","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403748","article-title":"High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia","volume":"19","author":"Heintel","year":"2005","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0742-6","article-title":"IGHV gene mutational status and LPL\/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide","volume":"88","author":"Maloum","year":"2009","journal-title":"Ann Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/35020592","article-title":"Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice","volume":"406","author":"Artandi","year":"2000","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13023","article-title":"Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease","volume":"167","author":"Lin","year":"2014","journal-title":"Br J Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-272104","article-title":"Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis","volume":"116","author":"Lin","year":"2010","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-054916","article-title":"CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia","volume":"109","author":"Josefsson","year":"2007","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618470","article-title":"Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling","volume":"125","author":"Yeh","year":"2015","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1243790","article-title":"Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia","volume":"58","author":"De Luca","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-242719","article-title":"Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression","volume":"115","author":"Ghosh AK","year":"2010","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01752.x","article-title":"Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia","volume":"107","author":"Molica S","year":"1999","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(00)00097-7","article-title":"The levels of TNF\u03b1, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL)","volume":"25","author":"Mainou-Fowler T","year":"2001","journal-title":"Leuk Res"},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219","article-title":"The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia","volume":"100","author":"Ferrajoli","year":"2002","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01063-7","article-title":"CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia","volume":"35","author":"Sivina","year":"2021","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1371057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:35:54Z","timestamp":1715819754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1371057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":96,"alternative-id":["10.3389\/fonc.2024.1371057"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1371057","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"article-number":"1371057"}}